Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line durvalumab + tremelimumab versus platinum-based standard chemotherapy in advanced or metastatic NSCLC
CTR20170046Phase 3Active
- Sponsor
- MedImmune
- Start
- Apr 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started Apr 2017; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170046.